# A Study of Multiple Doses of ALXN2050 in Healthy Adults

> **NCT05047484** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN2050
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05047484
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2019-07-23
- **Final completion:** 2019-07-23
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047484, "A Study of Multiple Doses of ALXN2050 in Healthy Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05047484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*